ALS Ltd Stock
€12.20
Your prediction
ALS Ltd Stock
Pros and Cons of ALS Ltd in the next few years
Pros
Cons
Performance of ALS Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ALS Ltd | 0.830% | -0.820% | -0.820% | 34.444% | 35.196% | 65.753% | 105.085% |
| Seek Ltd | -0.680% | -5.229% | -7.643% | -5.229% | 6.618% | 11.538% | -1.361% |
| Downer EDI Ltd | 0.940% | -0.467% | 2.899% | 23.837% | 36.538% | 39.216% | 36.538% |
| Insperity Inc. | 0.710% | -24.742% | -25.128% | -60.272% | -59.724% | -73.929% | -62.323% |
News
Electromed Posts 17% Gain in Fiscal Q4
Electromed (NYSEMKT:ELMD), a medical device company specializing in airway clearance therapy, reported record financial results for the quarter and fiscal year ended August 26, 2025. The company’s
Clene Posts 70% Revenue Drop in Q2
Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important
Brainstorm Posts 43% EPS Gain in Q2
Brainstorm Cell Therapeutics (OTC:BCLI), a biotechnology developer focused on neurodegenerative diseases, released its second quarter 2025 results on August 14, 2025. The headline news was a GAAP


